Cat. No.: HY-B0313

Hydroxyurea

(Synonyms: Hydroxycarbamide)

33 Cited Publications

Avis client

Based on 33 publication(s) in Google Scholar

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.34%
CAS No.: 127-07-1
Formule: CH₄N₂O₂
Masse moléculaire:76.05

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Hydroxyurea Chemical Structure

CAS No.: 127-07-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (33)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

IC₅₀ & Target

HIV-1

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	CC₅₀	147 μM Compound: HU	Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay	[PMID: 33109398]
HCT-116	IC₅₀	223 μM Compound: Hydroxyurea	Cytostatic activity against human HCT116 cells Cytostatic activity against human HCT116 cells	[PMID: 19581098]
HeLa S3	ED₅₀	1.96 μg/mL Compound: hydroxyurea	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
K562	IC₅₀	687.94 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay	10.1007/s00044-010-9544-6
KB	ED₅₀	5.29 μg/mL Compound: hydroxyurea	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	ED₅₀	2.67 μg/mL Compound: hydroxyurea	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	82 μM Compound: Hydroxyurea	Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay	[PMID: 11784145]
L1210	IC₅₀	85 μM Compound: Hydroxyurea	Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of L1210 leukemic cell suspension from 24 to 48 hr after compound addition. Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of L1210 leukemic cell suspension from 24 to 48 hr after compound addition.	[PMID: 2709372]
MCF7	IC₅₀	>100 μM Compound: Hydroxyurea	Cytostatic activity against human MCF7 cells Cytostatic activity against human MCF7 cells	[PMID: 19581098]
MOLT-3	ED₅₀	3.18 μg/mL Compound: hydroxyurea	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
MOLT-4	IC₅₀	>100 μM Compound: Hydroxyurea	Cytostatic activity against human MOLT4 cells Cytostatic activity against human MOLT4 cells	[PMID: 19581098]
NCI-H460	IC₅₀	>100 μM Compound: Hydroxyurea	Cytostatic activity against human H460 cells Cytostatic activity against human H460 cells	[PMID: 19581098]
P388	IC₅₀	32 μM Compound: Hydroxyurea	Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition	[PMID: 2709372]
SW480	ED₅₀	4.79 μg/mL Compound: hydroxyurea	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
SW-620	IC₅₀	>100 μM Compound: Hydroxyurea	Cytostatic activity against human SW620 cells Cytostatic activity against human SW620 cells	[PMID: 19581098]
U373-MAGI	CC₅₀	252 μM Compound: Hydroxyurea	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U373-MAGI	EC₅₀	25.8 μM Compound: Hydroxyurea	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas	[PMID: 27117260]
U-937	IC₅₀	115 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay	10.1007/s00044-011-9778-y
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h	[PMID: 15863319]
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on vero cells infected with Toxoplasma gondii after 24 h Compound tested on vero cells infected with Toxoplasma gondii after 24 h	[PMID: 15863319]
Vero	IC₅₀	0.5 mM Compound: hydroxyurea	Inhibition of Toxoplasma gondii infected in african green monkey Vero cells Inhibition of Toxoplasma gondii infected in african green monkey Vero cells	[PMID: 17905587]
Vero	IC₅₀	1 mM Compound: hydroxyurea	Inhibition of uninfected african green monkey Vero cells Inhibition of uninfected african green monkey Vero cells	[PMID: 17905587]

In Vitro

Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases^[1]. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The ^Gγ: ^Aγ-globin mRNA is induced 0.30- to 8-fold in vitro^[2]. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 127-07-1
Appearance Solid
Masse moléculaire 76.05
Formule CH₄N₂O₂
Color White to off-white
SMILES

O=C(N)NO
Synonyms

Hydroxycarbamide
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (33)

All WBIPCell Imaging/StainingRT-PCRCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer. [Abstract]

2022 Oct 17;7(1):354. PMID: 36253371

Hydroxyurea purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2022 Oct 17;7(1):354. [Abstract]

H1650 cells were treated with HA-9104 (5, 10 μM) or Hydroxyurea (HU, 5 mM) for 2 h. Chromatin proteins were isolated from whole cell lysate, followed by Western blotting.
Mol Cancer

Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance. [Abstract]

2024 Apr 29;23(1):86. PMID: 38685067

Hydroxyurea purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]

The cell viability of the indicated T24 cells was determined after 48 h of continuous exposure to multiple concentrations of hydroxyurea (HU).
Cancer Res

SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]

2025 May 14. PMID: 40366633
Nat Commun

Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes. [Abstract]

2022 Aug 16;13(1):4822. PMID: 35973990

Hydroxyurea purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]

SA-β-Gal assays for WT and Irf8^-/- BMDMs treated with hydroxyurea (HU, 10 mM) or mitomycin C (MMC, 1µM) for 5 days. Scale bars, 200 μm.

Hydroxyurea purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]

qPCR analysis of the SASP genes in WT and Irf8^-/- BMDMs treated with hydroxyurea (HU, 10 mM) or mitomycin C (MMC, 1 µM) for 6 days.
ACS Nano

A Cancer Cell Selective Replication Stress Nano Amplifier Promotes Replication Fork Catastrophe to Overcome Radioresistance. [Abstract]

2023 Sep 26;17(18):18548-18561. PMID: 37706454
Mol Cell

Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]

2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721
Mol Cell

m6Am sequesters PCF11 to suppress premature termination and drive neuroblastoma differentiation. [Abstract]

2024 Nov 7;84(21):4142-4157.e14. PMID: 39481383
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Death Differ

Angiopoietin-like protein 8 directs DNA damage responses towards apoptosis by stabilizing PARP1-DNA condensates. [Abstract]

2025 Apr;32(4):672-688. PMID: 39592710
Cell Death Differ

The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cells. [Abstract]

2023 Apr;30(4):922-937. PMID: 36750717

Hydroxyurea purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 Apr;30(4):922-937. [Abstract]

The interaction between MARVELD1 and PARP1 is greatly enhanced following exposure to Hydroxyurea (HU) in HeLa (8 mM HU; 24 h) and HEK293T cells (4 mM HU; 24 h).
Cell Death Dis

RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment. [Abstract]

2026 Feb 26;17(1):275. PMID: 41748545
Cell Death Dis

DEPTOR is a direct p53 target that suppresses cell growth and chemosensitivity. [Abstract]

2020 Nov 12;11(11):976. PMID: 33184290
Cell Death Dis

Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway. [Abstract]

2020 Jun 15;11(6):464. PMID: 32541902
Cell Death Discov

NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer. [Abstract]

2025 Nov 10;11(1):520. PMID: 41213930
Proc Natl Acad Sci U S A

The RPA-RNF20-SNF2H cascade promotes proper chromosome segregation and homologous recombination repair. [Abstract]

2023 May 16;120(20):e2303479120. PMID: 37155876
Oncogene

The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor. [Abstract]

2025 Aug;44(29):2515-2529. PMID: 40316740
Cell Rep

PATZ1 condensation adjacent to PML nuclear bodies suppresses HBoV transcription as an intrinsic antiviral defense. [Abstract]

2026 May 28;45(6):117437. PMID: 42213790
J Exp Bot

A genome-wide survey of DNA methylation reveals hyper-methylation regulates after-ripening and dormancy of recalcitrant Panax notoginseng seeds. [Abstract]

2025 Jan 7:erae508. PMID: 39774902
EMBO Rep

Genotoxic stress triggers Scd6-dependent regulation of translation to modulate the DNA damage response. [Abstract]

2025 Apr 24. PMID: 40275106
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Eur J Pharmacol

VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]

2025 Sep 15:1003:177942. PMID: 40651787
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
J Cell Mol Med

Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. [Abstract]

2019 Oct;23(10):6797-6804. PMID: 31338966
J Biol Chem

Vpx requires active cellular dNTP biosynthesis to effectively counteract the anti-lentivirus activity of SAMHD1 in macrophages. [Abstract]

2023 Aug;299(8):104984. PMID: 37390988
Arch Biochem Biophys

Inhibitory effect of CP-25 on intimal formation and vascular hyperplasia via suppression of GRK2/ERK1/2/EVI1 signaling. [Abstract]

2020 Nov 15;694:108601. PMID: 32980350
Int J Dent

The Role of Hemoglobin in Temporomandibular Joint Osteoarthritis and the Therapeutic Potential of Hydroxyurea. [Abstract]

2026 May 19:2026:3607127. PMID: 42164273
bioRxiv

Oncometabolite fumarate impairs ATR-CHK1 signaling by succinating RPA1 in Fumarate Hydratase-deficient renal cell carcinoma cells. [Abstract]

2025 Dec 10:2025.12.08.692638. PMID: 41427347
bioRxiv

2025 March 06.
Res Sq

2024 Jul 02.
bioRxiv

2023 Dec 5.
Holistic Integrative Oncology

13 October 2022.

Solvant et solubilité

In Vitro:

H₂O : 50 mg/mL (657.46 mM; Need ultrasonic)

DMSO : 50 mg/mL (657.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

13.1492 mL

65.7462 mL

131.4924 mL

5 mM

2.6298 mL

13.1492 mL

26.2985 mL

10 mM

1.3149 mL

6.5746 mL

13.1492 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (1314.92 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocole

Animal Administration^[4]

Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (478 KB)
- English - EN (478 KB)
- Français - FR (478 KB)
- Deutsch - DE (478 KB)
- Norwegian - NO (478 KB)
- Español - ES (478 KB)
- Swedish - SV (478 KB)
- Italian - IT (478 KB)
- Korean - KR (478 KB)
- Portuguese - PT (478 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief]

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief]

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief]

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief]

[5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	13.1492 mL	65.7462 mL	131.4924 mL	328.7311 mL
	5 mM	2.6298 mL	13.1492 mL	26.2985 mL	65.7462 mL
	10 mM	1.3149 mL	6.5746 mL	13.1492 mL	32.8731 mL
	15 mM	0.8766 mL	4.3831 mL	8.7662 mL	21.9154 mL
	20 mM	0.6575 mL	3.2873 mL	6.5746 mL	16.4366 mL
	25 mM	0.5260 mL	2.6298 mL	5.2597 mL	13.1492 mL
	30 mM	0.4383 mL	2.1915 mL	4.3831 mL	10.9577 mL
	40 mM	0.3287 mL	1.6437 mL	3.2873 mL	8.2183 mL
	50 mM	0.2630 mL	1.3149 mL	2.6298 mL	6.5746 mL
	60 mM	0.2192 mL	1.0958 mL	2.1915 mL	5.4789 mL
	80 mM	0.1644 mL	0.8218 mL	1.6437 mL	4.1091 mL
	100 mM	0.1315 mL	0.6575 mL	1.3149 mL	3.2873 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Hydroxyurea

33 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Hydroxyurea

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Anti-Orthopoxvirus Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Cell Death Library

Multi-Target Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Publications Citing Use of MedChemExpress (MCE) Hydroxyurea

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (33)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Hydroxyurea Related Classifications

HY-B0313 Related Classifications